Nervenheilkunde 2016; 35(03): 137-151
DOI: 10.1055/s-0037-1616368
Leitlinie
Schattauer GmbH

Leitlinie zur Diagnostik, Therapie und Prophylaxe von Cluster-Kopfschmerz, anderen trigeminoautonomen Kopfschmerzen, schlafgebundenem Kopfschmerz und idiopathisch stechenden Kopfschmerzen

Überarbeitete Therapieempfehlungen der Deutschen Migräne- und Kopfschmerzgesellschaft in Zusammenarbeit mit der DGN, ÖKSG, SKGGuideline for diagnostic, therapy and prophylaxis of cluster headache, as trigemino-autonomic cephalgias, sleep associated headache and idiopathic headacheRevised therapy recommendations of the German Migraine and Headache Society in cooperation Working with the DGN, ÖKSG, SKG
A. May
1   Institut für Systemische Neurowissenschaften, Uniklinik Hamburg Eppendorf
,
S. Evers
2   Klinik für Neurologie, Krankenhaus Lindenbrunn, Coppenbrügge und Universitätsklinikum Münster
,
G. Brössner
3   Universitätsklinik für Neurologie, Innsbruck
,
T. Jürgens
4   Klinik für Neurologie, Universitätsklinik Rostock
,
A. R. Gantenbein
5   Neurorehabilitation, RehaClinic, Bad Zurzach, Schweiz
,
V. Malzacher
6   Neurologische Praxis, Reutlingen
,
A. Straube
7   Klinik und Poliklinik für Neurologie, Universität München Großhadern, München
› Author Affiliations
Further Information

Publication History

eingegangen am: 20 January 2016

angenommen am: 28 January 2016

Publication Date:
10 January 2018 (online)

Zusammenfassung

Nach der 2013 überarbeiteten IHS-Klassifikation werden der episodische und chronische Cluster-Kopfschmerz, die episodisch und chronisch paroxysmale Hemikranie und SUNCT-Syndrom (short-lasting unilateral neuralgiform headache with conjunctival injection and tearing) und das SUNA-Syndrom (short-lasting unilateral neuralgiform headache with autonomic symptoms) sowie die Hemicrania continua unter dem Begriff trigemino-autonome Kopfschmerzen (TAK) zusammengefasst. Sie unterscheiden sich in Dauer, Frequenz und Rhythmik der Schmerzattacken. Autonome Begleitsymptome wie ipsilaterale Lakrimation, konjunktivale Injektion, Rhinorrhoe, nasale Kongestion, Gesichtsschwitzen, Völlegefühl im Ohr und Lidschwellung treten mehr oder weniger stark ausgeprägt auf. Ein wesentliches weiteres Unterscheidungsmerkmal liegt in dem unterschiedlichen Ansprechen auf Indometacin: Der Cluster-Kopfschmerz und das SUNCT- und SUNA-Syndrom sprechen nicht auf Indometacin an, bei den anderen TAK ist Indometacin per definitionem effektiv. Grundsätzlich unterteilt sich die Therapie der TAK in eine Akuttherapie und eine medikamentöse Prophylaxe. Aufgrund der relativen Kürze der Attacken ist bei der paroxysmalen Hemicranie und beim SUNCT/SUNA-Syndrom keine Akuttherapie möglich, beim Cluster-Kopfschmerz sind orale Substanzen in der Regel nicht ausreichend rasch wirksam. Das größte Augenmerk der Therapie liegt daher stets auf der Prophylaxe. Die Therapie der TAK erfordert eine individuell auf den Patienten zugeschnittene Kombination der verschiedenen Therapieoptionen. Obwohl ausreichend gute, vergleichende Studien rar sind, kann in der Praxis in der Mehrzahl der Fälle eine positive Beeinflussung der Schmerzattacken erreicht werden. Nur in seltenen Fällen ist eine invasive Therapie nötig. Die Therapieempfehlungen stützen sich, soweit möglich, auf Kriterien der evidenzbasierten Medizin (EBM).

Summary

Following the 2013 IHS-classification, cluster headache, paroxysmal hemicrania, hemicrania continua and short-lasting unilateral neuralgiform headache with autonomic symptoms (SUNA) and conjunctival injection and tearing (SUNCT) are included into the classification as trigemino-autonomic cephalgias (TAC). The similarities of these syndromes suggest a considerable shared pathophysiology. These syndromes have in common that they involve activation of trigeminovascular nociceptive pathways with reflex cranial autonomic activation. Clinically, this physiology predicts pain with some combination of ipsilateral lacrimation, conjunctival injection, nasal congestion, facial sweating or eyelid oedema. Broadly the management of TAC comprises acute and prophylactic treatment. Some types of trigemino-autonomic headaches, such as paroxysmal hemicrania and hemicrania continua have, unlike cluster headaches, a very robust response to indometacin, leading to a consideration of indometacin-sensitive headaches. This review covers the clinical picture and therapeutic options. Although studies following the criteria of evidence based medicine (EBM) are rare, most patients can be treated sufficiently. In medically intractable patients promising invasive treatments have emerged.

 
  • Literatur

  • 1 Andersson PG, Jespersen LT. Dihydroergotamine nasal spray in the treatment of attacks of cluster headache. A double-blind trial versus placebo. Cephalalgia 1986; 6: 51-4.
  • 2 Antonaci F, Sjaastad O. Chronic paroxysmal hemicrania (CPH): a review of the clinical manifestations. Headache 1989; 29: 648-56.
  • 3 Bahra A, Goadsby PJ. Diagnostic delays and mismanagement in cluster headache. Acta Neurol Scand 2004; 109: 175-9.
  • 4 Bahra A, May A, Goadsby PJ. Cluster headache: A prospective clinical study with diagnostic implications. Neurology 2002; 58: 354-61.
  • 5 Bennett MH, French C, Schnabel A, Wasiak J, Kranke P. Normobaric and hyperbaric oxygen therapy for migraine and cluster headache. Cochrane Database Syst Rev. 2008 CD005219.
  • 6 Burns B, Watkins L, Goadsby PJ. Treatment of medically intractable cluster headache by occipital nerve stimulation: long-term follow-up of eight patients. Lancet 2007; 369: 1099-106.
  • 7 Cittadini E, May A, Straube A, Evers S, Bussone G, Goadsby PJ. Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebo-controlled, double-blind crossover study. Arch Neurol 2006; 63: 1537-42.
  • 8 Cohen A, Matharu M, Goadsby P. ECG abnormalities on verapamil in cluster headache. Cephalalgia 2005; 25: 1200.
  • 9 Cohen AS, Burns B, Goadsby PJ. High-flow oxygen for treatment of cluster headache: a randomized trial. Jama 2009; 302: 2451-7.
  • 10 Ekbom K. Evaluation of clinical criteria for cluster headache with special reference to the classification of the International Headache Society. Cephalalgia 1990; 10: 195-7.
  • 11 Ekbom K. Lithium for cluster headache: review of the literature and preliminary results of long-term treatment. Headache 1981; 21: 132-9.
  • 12 Ekbom K. Treatment of acute cluster headache with sumatriptan. N Eng J Med 1991; 322-326.
  • 13 Ekbom K, Monstad I, Prusinski A, Cole JA, Pilgrim AJ, Noronha D. Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. The Sumatriptan Cluster Headache Study Group. Acta Neurol Scand 1993; 88: 63-9.
  • 14 Evers S, Goadsby PJ. Hypnic headache: clinical features, pathophysiology, and treatment. Neurology 2003; 60: 905-9.
  • 15 Favoni V, Grimaldi D, Pierangeli G, Cortelli P, Cevoli S. SUNCT/SUNA and neurovascular compression: new cases and critical literature review. Cephalalgia Int J Headache 2013; 33: 1337-1348.
  • 16 Fontaine D, Lanteri-Minet M, Ouchchane L, Lazorthes Y, Mertens P, Blond S, Geraud G, Fabre N, Navez M, Lucas C, Dubois F, Sol JC, Paquis P, Lemaire JJ. Anatomical location of effective deep brain stimulation electrodes in chronic cluster headache. Brain 2010; 133: 1214-23.
  • 17 Fontaine D, Lazorthes Y, Mertens P, Blond S, Geraud G, Fabre N, Navez M, Lucas C, Dubois F, Gonfrier S, Paquis P, Lanteri-Minet M. Safety and efficacy of deep brain stimulation in refractory cluster headache: a randomized placebo-controlled double-blind trial followed by a 1-year open extension. J Headache Pain 2010; 11: 23-31.
  • 18 Gallagher RM, Mueller LL, Freitag FG. Divalproex sodium in the treatment of migraine and cluster headaches. J Am Osteopath Assoc 2002; 102: 92-4.
  • 19 Gaul C, Christmann N, Schröder D, Weber R, Shanib H, Diener HC, Holle D. Differences in clinical characteristics and frequency of accompanying migraine features in episodic and chronic cluster headache. Cephalalgia Int J Headache 2012; 32: 571-577.
  • 20 Gaul C, Diener H-C, Silver N, Magis D, Reuter U, Andersson A, Liebler EJ, Straube A. PREVA Study Group. Non-invasive vagus nerve stimulation for PREVention and Acute treatment of chronic cluster headache (PREVA): A randomised controlled study. Cephalalgia Int J Headache. 2015 epub ahead of print.
  • 21 Gaul C, Holle D, May A. (Update on trigeminal autonomic cephalalgia). Nervenarzt 2013; 84: 1451-1459.
  • 22 Gaul C, Jürgens T. Frovatriptan for Prophylactic Treatment of Cluster Headache. Headache J Head Face Pain 2011; 51: 1008-1009.
  • 23 Goadsby PJ. Lacrimation, conjunctival injection, nasal symptoms. cluster headache, migraine and cranial autonomic symptoms in primary headache disorders – what’s new?. J Neurol. Neurosurg Psychiatry 2009; 80: 1057-1058.
  • 24 Goadsby PJ, Cittadini E, Burns B, Cohen AS. Trigeminal autonomic cephalalgias: diagnostic and therapeutic developments. Curr Opin Neurol 2008; 21: 323-30.
  • 25 Goadsby PJ, Lipton RB. A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases. Brain 1997; 120: 193-209.
  • 26 Goadsby PJ, Schoenen J, Ferrari MD, Silberstein SD, Dodick D. Towards a definition of intractable headache for use in clinical practice and trials. Cephalalgia 2006; 26: 1168-70.
  • 27 Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia Int J Headache 2013; 33: 629-808.
  • 28 Holle D, Naegel S, Obermann M. Hypnic headache. Cephalalgia Int J Headache 2013; 33: 1349-1357.
  • 29 Jürgens TP, Schoenen J, Rostgaard J, Hillerup S, Láinez MJ, Assaf AT, May A, Jensen RH. Stimulation of the sphenopalatine ganglion in intractable cluster headache: Expert consensus on patient selection and standards of care. Cephalalgia Int J Headache 2014; 34 (13) 1100-10.
  • 30 Jürgens TP, Schulte LH, May A. Oxygen treatment is effective in migraine with autonomic symptoms. Cephalalgia Int J Headache 2013; 33: 65-67.
  • 31 Law S, Derry S, Moore RA. Triptans for acute cluster headache. Cochrane Database Syst Rev. 2013 7. CD008042.
  • 32 Leone M, Attanasio A, Croci D, D’Amico D, Grazzi L, Ferraris A, Nespolo A, Bussone G. Neuroendocrinology of cluster headache. Ital J Neurol Sci 1999; 20: S18-S20.
  • 33 Leone M, Franzini A, Broggi G, May A, Bussone G. Long-term follow-up of bilateral hypothalamic stimulation for intractable cluster headache. Brain 2004; 127: 2259-64.
  • 34 Leone M, Franzini A, Cecchini AP, Mea E, Broggi G, Bussone G. Cluster headache: pharmacological treatment and neurostimulation. Nat Clin Pr Neurol 2009; 5: 153-62.
  • 35 Leroux E, Valade D, Taifas I, Vicaut E, Chagnon M, Roos C, Ducros A. Suboccipital steroid injections for transitional treatment of patients with more than two cluster headache attacks per day: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2011; 10: 891-897.
  • 36 Magis D, Allena M, Bolla M, De Pasqua V, Remacle JM, Schoenen J. Occipital nerve stimulation for drug-resistant chronic cluster headache: a prospective pilot study. Lancet Neurol 2007; 6: 314-21.
  • 37 Manzoni GC, Maffezzoni M, Lambru G, Lana S, Latte L, Torelli P. Late-onset cluster headache: some considerations about 73 cases. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 2012; 33 (Suppl. 01) S157-159.
  • 38 Markley HG. Topical agents in the treatment of cluster headache. Curr Pain Headache Rep 2003; 7: 139-43.
  • 39 Marmura MJ, Pello SJ, Young WB. Interictal pain in cluster headache. Cephalalgia 2010; 30: 1531-4.
  • 40 Martelletti P, Jensen RH, Antal A, Arcioni R, Brighina F, de Tommaso M, Franzini A, Fontaine D, Heiland M, Jürgens TP, Leone M, Magis D, Paemeleire K, Palmisani S, Paulus W, May A. Neuromodulation of chronic headaches: position statement from the European Headache Federation. J Headache Pain 2013; 14: 86.
  • 41 Matharu MS, Boes CJ, Goadsby PJ. Management of trigeminal autonomic cephalgias and hemicrania continua. Drugs 2003; 63: 1637-77.
  • 42 Matharu MS, Cohen AS, Boes CJ, Goadsby PJ. Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing syndrome: a review. Curr Pain Headache Rep 2003; 7: 308-18.
  • 43 Matharu MS, Levy MJ, Meeran K, Goadsby PJ. Subcutaneous octreotide in cluster headache: Randomized placebo-controlled double-blind crossover study. Ann Neurol 2004; 56: 488-494.
  • 44 May A. Cluster headache: pathogenesis, diagnosis, and management. Lancet 2005; 366: 843-55.
  • 45 May A. Diagnosis and clinical features of trigemino-autonomic headaches. Headache 2013; 53: 1470-1478.
  • 46 May A. Pearls and pitfalls: Neuroimaging in headache. Cephalalgia Int J Headache 2013; 33: 554-565.
  • 47 May A, Bahra A, Buchel C, Frackowiak RS, Goads-by PJ. PET and MRA findings in cluster headache and MRA in experimental pain. Neurology 2000; 55: 1328-35.
  • 48 May A, Dodick D. Headache research: A string of pearls. Cephalalgia Int J Headache 2013; 33: 505.
  • 49 May A, Evers S, Straube A, Pfaffenrath V, Diener H. Therapie und Prophylaxe von Cluster Kopfschmerzen und anderen Trigemino-Autonomen Kopfschmerzen. Überarbeitete Empfehlungen der Deutschen Migräne- und Kopfschmerzgesellschaft Nervenheilkunde 2004; 23: 478-490.
  • 50 May A, Straube A, Peikert A, Pfaffenrath V, Sandor P, Lampl C, Woeber C, Diener H. Diagnostik und apparative Zusatzuntersuchungen bei Kopfschmerzen. Stuttgart: Thieme; 2008
  • 51 McGeeney BE. Topiramate in the treatment of cluster headache. Curr Pain Headache Rep 2003; 7: 135-8.
  • 52 Nagy AJ, Gandhi S, Bhola R, Goadsby PJ. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology 2011; 77: 1827-1832.
  • 53 Nesbitt AD, Marin JCA, Tompkins E, Ruttledge MH, Goadsby PJ. Initial use of a novel noninvasive vagus nerve stimulator for cluster headache treatment. Neurology 2015; 84: 1249-1253.
  • 54 Paemeleire K, Bahra A, Evers S, Matharu MS, Goadsby PJ. Medication-overuse headache in patients with cluster headache. Neurology 2006; 67: 109-13.
  • 55 Pageler L, Katsarava Z, Lampl C, Straube A, Evers S, Diener HC, Limmroth V. Frovatriptan for prophylactic treatment of cluster headache: lessons for future trial design. Headache 2010; 51: 129-34.
  • 56 Pareja JA, Ruiz J, de Isla C, al-Sabbah H, Espejo J. Idiopathic stabbing headache (jabs and jolts syndrome). Cephalalgia 1996; 16: 93-6.
  • 57 Peres MF, Rozen TD. Melatonin in the preventive treatment of chronic cluster headache. Cephalalgia 2001; 21: 993-5.
  • 58 Pringsheim T, Magnoux E, Dobson CF, Hamel E, Aube M. Melatonin as adjunctive therapy in the prophylaxis of cluster headache: a pilot study. Headache 2002; 42: 787-92.
  • 59 Schoenen J, Jensen RH, Lantéri-Minet M, Láinez MJ, Gaul C, Goodman AM, Caparso A, May A. Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: A randomized, sham-controlled study. Cephalalgia Int J Headache 2013; 33 (10) 816-30.
  • 60 Schurks M, Kurth T, de Jesus J, Jonjic M, Rosskopf D, Diener HC. Cluster headache: clinical presentation, lifestyle features, and medical treatment. Headache 2006; 46: 1246-54.
  • 61 Schytz HW, Barløse M, Guo S, Selb J, Caparso A, Jensen R, Ashina M. Experimental activation of the sphenopalatine ganglion provokes cluster-like attacks in humans. Cephalalgia Int J Headache 2013; 33 (10) 831-41.
  • 62 Silberstein SD, Schulman EA, Hopkins MM. Repetitive intravenous DHE in the treatment of refractory headache. Headache 1990; 30: 334-9.
  • 63 Sjaastad O. Cluster Headache Syndrome. London: W B Saunders Company Ltd; 1992
  • 64 Sjaastad O, Bakketeig LS. Cluster headache prevalence. Vaga study of headache epidemiology. Cephalalgia 2003; 23: 528-33.
  • 65 Sjaastad O, Pettersen H, Bakketeig LS. The Vaga study; epidemiology of headache I: the prevalence of ultrashort paroxysms. Cephalalgia 2001; 21: 207-15.
  • 66 Stochino ME, Deidda A, Asuni C, Cherchi A, Manchia M, Del Zompo M. Evaluation of lithium response in episodic cluster headache: a retrospective case series. Headache 2012; 52: 1171-1175.
  • 67 Tronvik E, Wienecke T, Monstad I, Dahløf C, Bøe MG, Tjensvoll AB, Salvesen R, Zwart JA, Jansson S-O, Stovner LJ. Randomised trial on episodic cluster headache with an angiotensin II receptor blocker. Cephalalgia 2013; 33: 1026-1034.
  • 68 Zhu S, McGeeney B. When indomethacin fails: additional treatment options for “indomethacin responsive headaches.”. Curr Pain Headache Rep 2015; 19: 7.